Dr. Graff on the FDA Approval of Sacituzumab Govitecan in TNBC
April 22nd 2020Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the FDA approval of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC).
Read More
Stephanie Graff, MD: Information Is Power for Patients With Breast Cancer
January 1st 2020Stephanie L. Graff, MD, shared the importance of personalizing care for her patients with breast cancer, how she balances her professional and personal life, using the optimal voice on social media, and her vision for the future of breast cancer treatment.
Read More
Dr. Graff on Current Treatments in ESR1-Mutant Breast Cancer
September 25th 2019Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses current treatments in ESR1-mutant breast cancer.
Read More
Dr. Graff Underscores Unmet Needs in ESR1-Mutated Breast Cancer
September 9th 2019Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses some unmet needs of patients with ESR1-mutated metastatic breast cancer.
Read More
Dr. Graff Discusses Optimal Dosing of Tamoxifen in Breast Cancer
February 26th 2019Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses patient factors used to consider optimal treatment duration of tamoxifen in patients with breast cancer.
Read More
Dr. Graff on Tamoxifen De-Escalation in Breast Cancer
February 1st 2019Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health, and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses the use of tamoxifen in the treatment of patients with breast cancer.
Read More
Dr. Graff on Novel Therapies in Metastatic Breast Cancer
September 21st 2018Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses novel therapies for patients with metastatic breast cancer.
Read More
Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer
July 24th 2018Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.
Read More